TRASTUZUMAB DERUXTECAN: NOVEL ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN PATIENTS WITH GASTRIC ADENOCARCINOMA
Transtuzumab Deruxtecan in patients with gastric adenocarcinoma
Abstract
Gastric cancer (GC) is one of the main causes of death from cancer with a multifactorial origin and is characterized by the expression of a gene known as HER2. This gene promotes cell proliferation and prevents apoptosis of cancer cells, facilitating uncontrolled cell growth. Trastuzumab Deruxtecan (T-DXd) is a drug for the treatment of tumors with a heterogeneous expression of HER2 that are resistant to conventional anti-HER2 therapy. It is believed that the positive results obtained from Trastuzumab Deruxtecan in the treatment of
gastric cancer are related to its potent inhibitory effect of topoisomerase I, the stability of the linker in plasma, as well as its bystander effect. Furthermore, the drug is more efficiently delivered to its target (tumor cell), resulting in a higher concentration of the cytotoxic agent at the site of action. Another point to highlight is that trastuzumab deruxtecan has benefits in treating breast cancer compared to other anti-HER2 therapies since more patients using this drug presented positive responses compared to trastuzumab emtansine (TDM1), in addition to presenting longer survival and fewer adverse effects. Thus, this literature review shows that T-DXd is a promising therapy of extreme importance and with great capability to respond to cancers with low expression of HER2 and to HER2-positive cancers that are insensitive to the trastuzumab emtansine drug.
Downloads
All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)
Under this license, you are free to:
- Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt- remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Copyright policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
Licensing policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
